Karen S. Hartl
Bristol-Myers Squibb
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Karen S. Hartl.
Bioorganic & Medicinal Chemistry Letters | 2002
James C. Sutton; Scott A. Bolton; Karen S. Hartl; Ming-Hsing Huang; Glenn Anthony Jacobs; Wei Meng; Martin L. Ogletree; Zulan Pi; William A. Schumacher; Steven M. Seiler; William A. Slusarchyk; Uwe D. Treuner; Robert Zahler; Guohua Zhao; Gregory S. Bisacchi
A series of N1-activated C4-carboxy azetidinones was prepared and tested as inhibitors of human tryptase. The key stereochemical and functional features required for potency, serine protease specificity and aqueous stability were determined. From these studies compound 2, BMS-262084, was identified as a potent and selective tryptase inhibitor which, when dosed intratracheally in ovalbumin-sensitized guinea pigs, reduced allergen-induced bronchoconstriction and inflammatory cell infiltration into the lung.
Bioorganic & Medicinal Chemistry Letters | 2002
William A. Slusarchyk; Scott A. Bolton; Karen S. Hartl; Ming-Hsing Huang; Glenn Anthony Jacobs; Wei Meng; Martin L. Ogletree; Zulan Pi; William A. Schumacher; Steven M. Seiler; James C. Sutton; Uwe D. Treuner; Robert Zahler; Guohua Zhao; Gregory S. Bisacchi
The serine protease tryptase has been implicated in allergic and inflammatory diseases and associated with asthma. The synthesis and SAR of a series of N1-activated-4-carboxy azetidinones are described, resulting in identification of BMS-363131 (2) as a potent inhibitor of human tryptase (IC(50)<1.7 nM) with high selectivity (>3000-fold) for tryptase versus related serine proteases including trypsin.
Journal of Medicinal Chemistry | 2008
Yan Shi; Doree Sitkoff; Jing Zhang; Herbert E. Klei; Kevin Kish; Eddie C.-K. Liu; Karen S. Hartl; Steve M. Seiler; Ming Chang; Christine Huang; Sonia Youssef; Thomas E. Steinbacher; William A. Schumacher; Nyeemah Grazier; Andrew T. Pudzianowski; Atsu Apedo; Lorell Discenza; Joseph Yanchunas; Philip D. Stein; Karnail S. Atwal
An indole-based P1 moiety was incorporated into a previously established factor Xa inhibitor series. The indole group was designed to hydrogen-bond with the carbonyl of Gly218, while its 3-methyl or 3-chloro substituent was intended to interact with Tyr228. These interactions were subsequently observed in the X-ray crystal structure of compound 18. SAR studies led to the identification of compound 20 as the most potent FXa inhibitor in this series (IC(50) = 2.4 nM, EC(2xPT) = 1.2 microM). An in-depth energetic analysis suggests that the increased binding energy of 3-chloroindole-versus 3-methylindole-containing compounds in this series is due primarily to (a) the more hydrophobic nature of chloro- versus methyl-containing compounds and (b) an increased interaction of 3-chloroindole versus 3-methylindole with Gly218 backbone. The stronger hydrophobicity of chloro- versus methyl-substituted aromatics may partly explain the general preference for chloro- versus methyl-substituted P1 groups in FXa, which extends beyond the current series.
Bioorganic & Medicinal Chemistry Letters | 2013
Scott A. Bolton; James Sutton; Rushith Anumula; Gregory S. Bisacchi; Bruce L. Jacobson; William A. Slusarchyk; Uwe D. Treuner; Shung C. Wu; Guohua Zhao; Zulan Pi; Steven Sheriff; Rebecca A. Smirk; Sharon N. Bisaha; Daniel L. Cheney; Anzhi Wei; William A. Schumacher; Karen S. Hartl; Eddie C.-K. Liu; Robert Zahler; Steven M. Seiler
In this Letter, we describe the synthesis of several nonamidine analogs of biaryl acid factor VIIa inhibitor 1 containing weakly basic or nonbasic P1 groups. 2-Aminoisoquinoline was found to be an excellent surrogate for the benzamidine group (compound 2) wherein potent inhibition of factor VIIa is maintained relative to most other related serine proteases. In an unanticipated result, the m-benzamide P1 (compounds 21a and 21b) proved to be a viable benzamidine replacement, albeit with a 20-40 fold loss in potency against factor VIIa.
Journal of Medicinal Chemistry | 1996
Michael S. Bernatowicz; Clifford E. Klimas; Karen S. Hartl; Marianne Peluso; Nick J. Allegretto; Steven M. Seiler
European Journal of Pharmacology | 2007
William A. Schumacher; Steven E. Seiler; Thomas E. Steinbacher; Anne B. Stewart; Jeffrey S. Bostwick; Karen S. Hartl; Eddie C.-K. Liu; Martin L. Ogletree
Bioorganic & Medicinal Chemistry Letters | 2004
James C. Sutton; Scott A. Bolton; Malcolm E. Davis; Karen S. Hartl; Bruce L. Jacobson; Arvind Mathur; Martin L. Ogletree; William A. Slusarchyk; Robert Zahler; Steven M. Seiler; Gregory S. Bisacchi
Journal of Medicinal Chemistry | 1993
Nicholas A. Meanwell; Rosenfeld Mj; John J Wright; Catherine L. Brassard; John O. Buchanan; Marianne E. Federici; J. S. Fleming; Marianne Gamberdella; Karen S. Hartl; George B. Zavoico
Bioorganic & Medicinal Chemistry Letters | 2004
Gregory S. Bisacchi; William A. Slusarchyk; Scott A. Bolton; Karen S. Hartl; Glenn Anthony Jacobs; Arvind Mathur; Wei Meng; Martin L. Ogletree; Zulan Pi; James C. Sutton; Uwe D. Treuner; Robert Zahler; Guohua Zhao; Steven M. Seiler
Bioorganic & Medicinal Chemistry Letters | 2004
Guohua Zhao; Scott A. Bolton; Chet Kwon; Karen S. Hartl; Steven M. Seiler; William A. Slusarchyk; James C. Sutton; Gregory S. Bisacchi